Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 3/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424533 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL1955384 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL2948034 | 0.88 | CASP3 (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL15873350 | 0.86 | CASP3 (0.48) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL31450833 | 0.86 | CASP3 (0.48) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL15873353 | 0.86 | CASP3 (0.48) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL31451006 | 0.86 | CASP3 (0.48) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL26648244 | 0.86 | CASP3 (0.44) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL26648240 | 0.86 | CASP3 (0.44) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL28372102 | 0.85 | KMT2A (0.52) | KMT2ACASP3MDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | KMT2A 2454/4885CASP3 64/4885MDM4 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.